Narrative review on multi-omics for spondyloarthritis and psoriatic arthritisNew multi-omics strategies help doctors better understand spondyloarthritis and psoriatic arthritis conditions

Frontiers in Medicine Published May 12, 2026 Study authors: Minshun Zhu, Renzhong Li, Sanbing Wu, Jiaping Chen, Kui Sun DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider multi-omics as a conceptual framework for spondyloarthritis research, not a proven clinical tool.

This is a narrative review that synthesizes existing literature on multi-omics strategies for spondyloarthritis and psoriatic arthritis. The scope covers the potential of integrating genomics, transcriptomics, proteomics, and microbiomics compared to single-omics approaches. The authors argue that such integration could help elucidate shared and distinct immunopathological mechanisms, facilitate differential diagnosis, discover novel biomarkers, advance early diagnosis, enable precision monitoring, predict treatment responses, and identify novel therapeutic targets. The review does not report a pooled effect size or specific study populations, as it is a qualitative synthesis. Key limitations noted by the authors include the absence of reported primary trial data and the conceptual nature of the hypotheses discussed. The authors acknowledge that the evidence base is preliminary and that clinical implementation requires further validation. Practice relevance is not reported, and the findings should be interpreted as mechanistic hypotheses rather than proven clinical strategies.

Medical experts are looking at many different types of biological data to understand these joint diseases. They combine information from genes, proteins, and gut bacteria to get a full picture of what is happening inside the body. This approach is much more detailed than looking at just one type of data at a time.

Using these combined tools, researchers hope to find why some patients get sick while others do not. They want to discover new markers that can help doctors tell the difference between similar diseases. This could lead to faster diagnoses and more accurate treatment plans for everyone who needs them.

The goal is to predict how a person will respond to specific medicines before starting treatment. By understanding the unique biology of each patient, doctors can choose the best therapy sooner. This personalized approach may also help scientists find new targets for future medicines.

While this is a review of existing studies, it shows great promise for the future. More research is needed to prove these ideas work in real life. Until then, this knowledge helps guide how doctors think about these complex conditions.

What this means for you:

Combining genetic and protein data helps doctors understand spondyloarthritis and psoriatic arthritis better and find new treatments.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Spondyloarthritis (SpA) and psoriatic arthritis (PsA) are interrelated, immune-mediated inflammatory diseases characterized by significant clinical heterogeneity. Early differential diagnosis, accurate disease activity assessment, and the development of personalized treatment strategies remain significant clinical challenges. Single-omics approaches have provided only a limited view of this complexity, highlighting the need for integrative strategies. This review systematically synthesizes findings from multi-omics studies—including genomics, transcriptomics, proteomics, and microbiomics—in SpA and PsA. We focus on their application in three key areas: (i) elucidating shared and distinct immunopathological mechanisms, (ii) facilitating differential diagnosis, and (iii) discovering novel biomarkers. By comparing their molecular landscapes, we explore the shared and distinct immunological foundations of SpA and PsA. Furthermore, we critically evaluate the translational potential of integrated multi-omics strategies for advancing early diagnosis, precision monitoring, predicting treatment responses, and identifying novel therapeutic targets. This integrated, multi-omics framework promises to refine disease taxonomy and guide personalized therapeutic decisions, paving the way for precision medicine in SpA and PsA.

Narrative review on multi-omics for spondyloarthritis and psoriatic arthritisNew multi-omics strategies help doctors better understand spondyloarthritis and psoriatic arthritis conditions

Study Details

Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis

Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients

Clinical research that matters. Delivered to your inbox.

Narrative review on multi-omics for spondyloarthritis and psoriatic arthritisNew multi-omics strategies help doctors better understand spondyloarthritis and psoriatic arthritis conditions

More on Rheumatoid Arthritis

Study Details

Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis

Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients

Clinical research that matters. Delivered to your inbox.

Related in Rheumatology

From Other Specialties